Cytokinetics Offers Update on Development Program for Tirasemtiv
October 20, 2014 at 07:33 AM EDT
Cytokinetics, Incorporated (Nasdaq: CYTK) provided a program update today relating to tirasemtiv, the company's lead drug candidate ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.